EGFR and non-small cell lung carcinoma: In this study, a total of 86 patients with non-small-cell lung cancer who were treated in our hospital were selected as the main observation objects of this research analysis, and the clinical intervention effect, immune function, serum EGFR level, and serum progesterone after targeted therapy with afatinib were further observed, aiming to provide a basis for clinical intervention in patients with non-small-cell lung cancer.